Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT)
Wang, SV
; Sreedhara, SK; Schneeweiss, S and REPEAT Initiative
(2021).
Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT).
[Dataset].
OSF.
https://doi.org/10.17605/OSF.IO/MY5GN
; Sreedhara, SK; Schneeweiss, S and REPEAT Initiative
(2021).
Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT).
[Dataset].
OSF.
https://doi.org/10.17605/OSF.IO/MY5GN
Studies that generate real-world evidence (RWE) through analysis of routinely collected healthcare data provide key insights for regulators, payers, and other healthcare decision-makers. In this project, we evaluated clarity of methodology reporting for 250 RWE studies and attempted to reproduce 150 studies using the same data sources and methods reported by the original investigators.
Keywords
Epidemiology; Outcomes research| Item Type | Dataset |
|---|---|
| Resource Type |
Resource Type Resource Description Dataset Quantitative |
| Capture method | Unknown |
| Date | 23 March 2021 |
| Language(s) of written materials | English |
| Creator(s) |
Wang, SV; Sreedhara, SK; Schneeweiss, S and REPEAT Initiative
|
| LSHTM Faculty/Department | Academic Services & Administration > Directorate |
| Participating Institutions | Brigham and Women’s Hospital, Boston, United States; Harvard Medical School, Boston, United States; Aetion, Inc., New York, United States; Avalere Health, Washington, United States; UCB Pharma, Brussels, Germany; GSK, Middlesex, London, United Kingdom; IQVIA, London, United Kingdom; National Taiwan University, Taipei, Taiwan; Ewha Womans University, Seoul, South Korea; McGill University, Montreal, Canada; Lady Davis Institute, Jewish General Hospital, Montreal, Canada; University of Southern Denmark, Odense, Denmark; University of Florida College of Pharmacy, Gainesville, United States; University of Pennsylvania, Philadelphia, United States; National Institute for Health and Care Excellence, London, United Kingdom; Novartis Pharmaceuticals Corporation, East Hanover, United States; Janssen-Cilag B.V., Breda, Netherlands; Food and Drug Administration, Silver Spring, United States; Center for Open Science, Charlottesville, United States; Optum Epidemiology, Optum, Eden Prairie, United States; Humana, Washington, DC, United States; London School of Hygiene and Tropical Medicine, London, United Kingdom; Aarhus University, Aarhus, Denmark; Journal of Clinical Epidemiology, Ottawa, Canada; The International Society for Health Economics and Outcomes Research, Lawrenceville, United States; Baylor College of Medicine, Houston, United Kingdom; European Medicines Agency, Amsterdam, Netherlands; Johnson & Johnson, New Brunswick, United States; Amgen Inc., Thousand Oaks, United States; Northwestern Memorial Hospital, Chicago, United States; CVS Health, Woonsocket, United States; Maastricht University Medical Center+, Maastricht, Netherlands; Federation of Austrian Social Insurances, Vienna, Austria; Connecticut Center for Patient Safety, LLC, Fairfield, United States; Stanford University, Stanford, United States; Sanofi S.A., Paris, France; Annals of Internal Medicine, Philadelphia, United States; The BMJ, London, United Kingdom; Pharmaceuticals and Medical Devices Agency, Tokyo, Japan |
| Funders |
Project Funder Grant Number Funder URI |
| Date Deposited | 19 Jan 2023 16:45 |
| Last Modified | 18 Nov 2025 09:14 |
| Publisher | OSF |
No files available. Please consult associated links.
